Evidence map›Paper›PMID 29560855›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2018

Integrating hepatitis B, hepatitis C and HIV screening into tuberculosis entry screening for migrants in the Netherlands, 2013 to 2015.

Janneke P Bil, Peter Ag Schrooders, Maria Prins, Peter M Kouw, Judith He Klomp, Maarten Scholing, Lutje Phm Huijbregts, Gerard Jb Sonder, Toos Chfm Waegemaekers, Henry Jc de Vries and 3 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Screening for infectious diseases in newly arrived migrants in Europe: the context matters.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018
    Article
  14. Note from the editors: World Tuberculosis Day 2018 and Special issue-Screening and prevention of infectious diseases in newly arrived migrants in Europe.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018
    Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Janneke P BilDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Peter Ag SchroodersDepartment of Infectious Diseases, Public Health Service of Noord- en Oost-Gelderland, Warnsveld, the Netherlands.
Maria PrinsDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Peter M KouwDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Judith He KlompDepartment of Infectious Diseases, Public Health Service of Gelderland Zuid, Nijmegen, the Netherlands.
Maarten ScholingDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Lutje Phm HuijbregtsDepartment of Infectious Diseases, Public Health Service of Noord- en Oost-Gelderland, Warnsveld, the Netherlands.
Gerard Jb SonderDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Toos Chfm WaegemaekersNational Coordination Centre for Communicable Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Henry Jc de VriesDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Wieneke MeijerDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Freke R ZuureDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Alma TostmannThese authors share joint last authorship.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated uptake and diagnostic outcomes of voluntary hepatitis B (HBV) and C virus (HCV) screening offered during routine tuberculosis entry screening to migrants in Gelderland and Amsterdam, the Netherlands, between 2013 and 2015. In Amsterdam, HIV screening was also offered. Overall, 54% (461/859) accepted screening. Prevalence of chronic HBV infection (HBsAg-positive) and HCV exposure (anti-HCV-positive) in Gelderland was 4.48% (9/201; 95% confidence interval (CI): 2.37-8.29) and 0.99% (2/203; 95% CI: 0.27-3.52), respectively, all infections were newly diagnosed. Prevalence of chronic HBV infection, HCV exposure and chronic HCV infection (HCV RNA-positive) in Amsterdam was 0.39% (1/256; 95% CI: 0.07-2.18), 1.17% (3/256; 95% CI: 0.40-3.39) and 0.39% (1/256; 95% CI: 0.07-2.18), respectively, with all chronic HBV/HCV infections previously diagnosed. No HIV infections were found. In univariate analyses, newly diagnosed chronic HBV infection was more likely in participants migrating for reasons other than work or study (4.35% vs 0.83%; odds ratio (OR) = 5.45; 95% CI: 1.12-26.60) and was less likely in participants in Amsterdam than Gelderland (0.00% vs 4.48%; OR = 0.04; 95% CI: 0.00-0.69). Regional differences in HBV prevalence might be explained by differences in the populations entering compulsory tuberculosis screening. Prescreening selection of migrants based on risk factors merits further exploration.

Indexed as

Delivery of Health Care, IntegratedTransients and MigrantsAdolescentAdultAfricaAntibodies, ViralAsia, SoutheasternCaribbean RegionEurope, EasternFemaleHepatitis BHepatitis B Surface AntigensHepatitis CHepatitis C AntibodiesHIV InfectionsHumansAntibodies, ViralHepatitis B Surface AntigensHepatitis C Antibodieshepatitis B virushepatitis C virusHIV infectionmigrantsthe Netherlandstuberculosis

Identifiers

PMID29560855
PMCPMC5861593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.